Current injection-label evidence
Wegovy and Zepbound report product-specific hypotension patterns
The June 18, 2026 Wegovy label reports adverse reactions related to hypotension in 1.3% of Wegovy-treated adults versus 0.4% of placebo-treated adults in weight-reduction trials; syncope was reported in 0.8% versus 0.2%. The label says some reactions were related to gastrointestinal adverse reactions and volume loss, and hypotension or orthostatic hypotension was more frequent with concomitant antihypertensive therapy. The April 22, 2026 Zepbound injection label reports hypotension in 1.6% of Zepbound-treated participants versus 0.1% with placebo in pooled adult weight-reduction Studies 1 and 2. Among Zepbound-treated participants, the label reports 2.2% with concomitant antihypertensive therapy versus 1.2% without it and also associates hypotension with gastrointestinal adverse events and dehydration.
- Keep every percentage tied to its named product, studied population, trial pool, and label revision; Wegovy and Zepbound were not compared head to head in these data.
- These labels do not establish one class-wide hypotension rate, a guaranteed blood-pressure reduction, or an expected timeline for one patient.
- The Zepbound adverse-reaction table groups decreased blood pressure, hypotension, and orthostatic hypotension; it does not provide a separate rate for each term.
Low readings and dizziness
Symptoms, dehydration, and other medicines matter more than one isolated reading
Lightheadedness when standing, weakness, blurred vision, nausea, confusion, or fainting can occur with low blood pressure, but similar symptoms can also reflect dehydration, low blood sugar, anemia, infection, heart-rhythm problems, another medicine, or another medical condition. GLP-1-related nausea, vomiting, diarrhea, or markedly reduced intake can reduce circulating volume. Diuretics and other blood-pressure medicines may add context, while insulin or sulfonylureas can make glucose assessment important. A clinician should interpret the pattern rather than assuming the GLP-1 is the only cause.
- Record the reading, pulse, symptoms, whether they occur while standing or at rest, recent vomiting or diarrhea, fluid and food intake, urine output, illness, heat exposure, and all medication changes.
- Ask whether the home cuff and technique are reliable and whether the care team wants repeated readings, orthostatic measurements, glucose checks, kidney labs, or in-person assessment.
- Do not self-treat persistent symptoms with salt, electrolyte products, caffeine, skipped antihypertensives, extra fluids, or a GLP-1 dose change without individualized guidance.
High blood pressure
A GLP-1 is not a substitute for hypertension care
Some trial groups have shown average blood-pressure changes during weight-management treatment, but a group average is not a personal treatment plan and does not make semaglutide or tirzepatide an automatic replacement for antihypertensive therapy. High readings can reflect established hypertension, pain, stress, illness, stimulants or decongestants, missed cardiovascular medicine, measurement problems, or another condition. Eligibility and follow-up depend on the exact product, diagnosis, current control, cardiovascular and kidney history, symptoms, and the clinician who owns blood-pressure care.
- Continue prescribed cardiovascular medicines unless the clinician who manages them gives a specific change plan.
- Share uncontrolled or newly elevated readings, severe headache, chest symptoms, shortness of breath, new neurologic symptoms, swelling, pregnancy possibility, or recent medication changes promptly.
- Avoid sellers that promise a GLP-1 will cure hypertension, guarantee heart protection, or remove the need for primary-care or cardiology follow-up.
Medication coordination
Antihypertensive and diabetes medicines need one accountable plan
A safe GLP-1 review should identify why each cardiovascular medicine is used, who prescribes it, recent readings, kidney function when relevant, and whether gastrointestinal symptoms or weight change have altered the clinical picture. Diuretics, ACE inhibitors, ARBs, beta blockers, calcium channel blockers, alpha blockers, nitrates, and other heart medicines are not interchangeable. Diabetes medicines also matter because dizziness, weakness, sweating, or confusion can overlap with hypoglycemia, particularly with insulin or sulfonylureas.
- Ask which clinician owns blood-pressure medication changes and how the GLP-1 prescriber, primary-care clinician, cardiologist, nephrologist, endocrinologist, and pharmacist will share information.
- Bring the exact medication names, strengths, schedules, reasons for use, recent changes, refill gaps, supplements, alcohol, caffeine, nicotine, stimulants, and decongestants.
- Do not use a generic online hold chart to stop a diuretic, antihypertensive, diabetes medicine, or GLP-1 during symptoms, illness, fasting, travel, or a procedure.
Route and product identity
Injection-label findings do not automatically transfer to tablets or compounded products
Current Wegovy labeling includes semaglutide injection and once-daily oral tablets, while current Zepbound labeling covers tirzepatide injections in multiple presentations. The hypotension evidence on this page comes from the specific adult weight-reduction trial sections summarized by those labels and must remain product and study specific. A patient-specific compounded semaglutide or tirzepatide preparation is not an FDA-approved Wegovy or Zepbound finished drug product and may differ in concentration, inactive ingredients, presentation, container, pharmacy instructions, storage, and beyond-use date.
- Preserve the manufacturer or dispensing-pharmacy label, active ingredient, route, presentation, concentration or strength, refill or lot details, storage history, and a photo of the current package.
- Do not transfer a branded trial percentage, tablet instruction, pen instruction, or missed-dose rule to a compounded vial or another branded product.
- Avoid no-prescription sellers, research-use products, unverified additives, copied dosing charts, and claims that dizziness or low readings prove the product is working.